Pachychoroid‐phenotype effects on 5‐year visual outcomes of anti‐VEGF monotherapy in polypoidal choroidal vasculopathy
Pachychoroid‐phenotype effects on 5‐year visual outcomes of anti‐VEGF monotherapy in polypoidal choroidal vasculopathy
复制标题
厚脉络膜表型对息肉状脉络膜血管病抗 VEGF 单药治疗 5 年视力结果的影响
DOI：
10.1111/aos.15015
复制
发表时间：
2021
影响因子：
3.4
通讯作者：
Tsujikawa Akitaka
中科院分区：
文献类型：
--
作者：
Shimizu Yuichiro;Miyata Manabu;Ooto Sotaro;Miyake Masahiro;Mori Yuki;Tamura Hiroshi;Ueda‐Arakawa Naoko;Uji Akihito;Muraoka Yuki;Takahashi Ayako;Wakazono Tomotaka;Yamashiro Kenji;Hata Masayuki;Tsujikawa Akitaka
PurposeTo investigate whether efficacy of anti‐vascular endothelial growth factor（VEGF）monetary for polypoidal choroidal vasculopathy（PCV）different between pachychoroid and non-pachychoroid phenotype.MethodsThis retrospective longitudinal study includes 115 treatment-naïve eyes in 115 continuous patients with symptomatic PCV who were treated with anti‐VEGF monetary and were followed up for 5 years.合格的眼睛被分配到具有厚脉络膜表型的厚-PCV组或不具有厚脉络膜表型的非厚-PCV组。最佳矫正视力（BCVA）和其他参数超过5年的时间进行了比较groups.Results48眼和67眼被分为pachy-PCV和non-pachy-PCV组分别。肥厚-PCV组的基线和5年BCVA（最小分辨角的对数）分别为0.19 ± 0.20和0.16 ± 0.28，非肥厚-PCV组分别为0.25 ± 0.26和0.26 ± 0.36。两组的BCVA均无显著变化（分别为p = 0.18和0.08）。在任何观察时间点，组间BCVA均无差异。肥厚-PCV组基线和5年时的中心凹下脉络膜厚度（SFCT）显著高于非肥厚-PCV组（均P < 0.001）;然而，在5年期间，两组SFCT的平均下降率没有差异（22% vs. 23%，p = 0.81）.结论我们的研究结果表明，抗VEGF单药治疗对于患有PCV的厚脉络膜表型和非厚脉络膜表型眼睛同样有效，至少5年，尽管还需要进一步的研究。
PurposeTo investigate whether the efficacy of anti‐vascular endothelial growth factor (VEGF) monotherapy for polypoidal choroidal vasculopathy (PCV) differs between pachychoroid and non‐pachychoroid phenotypes in the long term.MethodsThis retrospective longitudinal study included 115 treatment‐naïve eyes in 115 consecutive patients with symptomatic PCV who were treated with anti‐VEGF monotherapy and were followed up for 5 years. Eligible eyes were assigned to either a pachy‐PCV group, with a pachychoroid phenotype, or a non‐pachy‐PCV group, without a pachychoroid phenotype. Best‐corrected visual acuity (BCVA) and other parameters over a 5‐year period were compared between the groups.ResultsForty‐eight eyes and 67 eyes were classified into the pachy‐PCV and non‐pachy‐PCV groups respectively. Baseline and 5‐year BCVA (logarithm of the minimum angle of resolution) were 0.19 ± 0.20 and 0.16 ± 0.28 in the pachy‐PCV group, respectively, and 0.25 ± 0.26 and 0.26 ± 0.36 in the non‐pachy‐PCV group respectively. BCVA did not change significantly in either group (p = 0.18 and 0.08 respectively). BCVA did not differ between the groups at any observation time‐point. Subfoveal choroidal thickness (SFCT) at baseline and at 5 years was significantly higher in the pachy‐PCV group than in the non‐pachy‐PCV group (both p < 0.001); however, the mean rate of decrease in SFCT did not differ in either group over the 5‐year period (22% vs. 23%, p = 0.81).ConclusionOur findings suggest that anti‐VEGF monotherapy was similarly effective for pachychoroid‐ and non‐pachychoroid‐phenotype eyes with PCV, for at least 5 years, although further studies are required.
登录
查看更多内容
影响因子：
3.4
作者：
Azar, Georges;Wolff, Benjamin;Lumbroso, Bruno
通讯作者：
Lumbroso, Bruno
影响因子：
13.7
作者：
Sadda, SriniVas R.;Tuomi, Lisa L.;Hopkins, J. Jill
通讯作者：
Hopkins, J. Jill
DOI：
10.1097/iae.0b013e3182953df4
发表时间：
2013-09-01
影响因子：
3.3
作者：
Warrow, David J.;Hoang, Quan V.;Freund, K. Bailey
通讯作者：
Freund, K. Bailey
DOI：
10.1097/iae.0000000000001451
发表时间：
2017-11-01
影响因子：
3.3
作者：
Wakazono, Tomotaka;Yamashiro, Kenji;Yoshimura, Nagahisa
通讯作者：
Yoshimura, Nagahisa
DOI：
10.1097/iae.0000000000000331
发表时间：
2015-01-01
影响因子：
3.3
作者：
Pang, Claudine E.;Freund, K. Bailey
通讯作者：
Freund, K. Bailey